Clinical Significance of Monitoring ETV6-RUNX1 Fusion Gene Expression in Children with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Y Hong,Y Z Qin,Y,S H Zhou,Y Wang,L P Xu,X H Zhang,X J Huang,X S Zhao

DOI: https://doi.org/10.3760/cma.j.issn.0253-2727.2017.08.006

2017-01-01

Abstract:Objective To investigate the clinical significance of monitoring ETV6-RUNX1 fusion gene in children with acute lymphoblastic leukemia (ALL) after allogeneic stem cell transplantation (alloHSCT).Methods Clinical data of 13 children received allo-HSCT in Peking University Institute of Hematology from May 2009 to March 2016 were retrospectively collected.The ETV6-RUNX1 gene was examined by real-time quantitative polymerase chain reaction (RQ-PCR).The correlation between its expression level and the disease status was analyzed.Results Of 13 enrolled ALL cases,the ETV6RUNX 1 expression of 7 patients converted to positive after transplant at a median time of 137 days (range,28-270 days).The expression level of the first positive sample was 0.034％ (range,0.004％-0.061％).The duration from ETV6-RUNX1 positive to hematological relapse was 196 days (range,28-666 days).Four patients experienced relapse at a median time of 294 days (range,104-803 days) after allo-HSCT.The ETV6-RUNX1 expression converted to positive prior to MRD.Patients with positive ETV6-RUNX1 gene expression pre-transplantation would be more likely to relapse.Conclusion Monitoring ETV6-RUNX1 by RQ-PCR could be used to evaluate MRD status after allo-HSCT.Patients with positive ETV6-RUNX1 after transplant had a poor prognosis.